- EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-AFR: MorphoSys AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
- EQS-AFR: MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
- EQS-News: MorphoSys AG: Financial Calendar 2023
- EQS-DD: MorphoSys AG: Krisja Vermeylen, buy
- EQS-DD: MorphoSys AG: Dr. Marc Cluzel, buy
- EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
- EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
- EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
MorphoSys AG (MOR:FRA) closed at 15.78, 12.79% above the 52 week low of 13.99 set on Nov 16, 2022.
13.99Nov 16 202235.86Dec 10 2021
Markit short selling activity
|Market cap||547.03m EUR|
|EPS (TTM)||-25.23 |
Data delayed at least 15 minutes, as of Dec 06 2022 17:57 GMT.